MOTS-c is a mitochondria-derived peptide that improves insulin sensitivity, metabolic flexibility, and exercise capacity. Complete dosing guide and lab tracking protocol.
Quick Summary - MOTS-c is a mitochondria-derived peptide encoded in mitochondrial DNA -- one of the only peptides of its kind - Primary effects: improved insulin sensitivity, metabolic flexibility, and exercise capacity - Endogenous MOTS-c levels decline with age and with metabolic disease -- supplementation aims to restore youthful signaling - Track fasting glucose, fasting insulin, HbA1c, and triglycerides to measure metabolic response - Typically used in cycles of 4-8 weeks at 5-10 mg subcutaneous 3-5 times weekly
Most peptides discussed in longevity medicine are derived from proteins found in human tissue or synthesized as analogs of naturally occurring signaling molecules. MOTS-c is different. It is encoded in mitochondrial DNA -- specifically the 12S rRNA gene -- making it one of the only known peptides of mitochondrial origin.
This is not a trivial distinction. Mitochondria are the energy-producing organelles in every cell, and they maintain their own separate genetic code (a remnant of their evolutionary origin as separate organisms). The discovery that mitochondrial DNA encodes signaling peptides like MOTS-c represents an entirely new category of biological communication that science is only beginning to understand.
MOTS-c is sometimes called a mitokine -- a mitochondria-derived signaling molecule that communicates metabolic status to other cells and organs. Its primary role appears to be coordinating the cellular response to metabolic stress, particularly insulin resistance.
Insulin sensitivity. MOTS-c activates AMPK (AMP-activated protein kinase), the cellular energy sensor that drives glucose uptake independent of insulin. In animal and human studies, MOTS-c administration improved insulin sensitivity in insulin-resistant states.
Metabolic flexibility. Metabolic flexibility -- the ability to efficiently switch between burning glucose and burning fat -- declines with age and metabolic disease. MOTS-c improves this switching capacity at the cellular level.
Exercise capacity and muscle function. MOTS-c levels rise naturally with exercise, and exogenous MOTS-c administration has been shown to improve exercise endurance in animal models through enhanced mitochondrial function.
Anti-obesity effects. In obese mouse models, MOTS-c reduced weight gain, improved lipid profiles, and reduced fatty liver -- effects driven by its metabolic reprogramming activity.
Age-related decline. Endogenous MOTS-c levels decline with age and are lower in individuals with type 2 diabetes and metabolic syndrome -- supporting the hypothesis that restoring MOTS-c levels may partially reverse age-related metabolic deterioration.
MOTS-c is one of the 14 peptides included in the RFK Jr. reclassification, expected to return to legal compounding status through licensed pharmacies.
Standard protocol:
Fasting glucose and fasting insulin: The primary metabolic targets. Calculate HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) = fasting glucose (mg/dL) multiplied by fasting insulin (uIU/mL) divided by 405. HOMA-IR under 1.5 is optimal. Track before cycle, at 4 weeks, and at 8 weeks.
HbA1c: 3-month average glucose -- confirms sustained metabolic improvement beyond the measurement window. Target 4.2-5.2%.
Triglycerides: MOTS-c lipid effects should reduce triglycerides in users with elevated baseline. Target under 100 mg/dL.
HDL-C: Metabolic improvement typically raises HDL. Target above 50 mg/dL (women), above 40 mg/dL (men).
ApoB: Tracks atherogenic particle burden -- should improve alongside triglycerides with metabolic optimization.
How is MOTS-c different from other metabolic peptides?
MOTS-c works at the mitochondrial level -- it is not mimicking a hormone or growth factor but rather restoring a fundamental cellular energy signaling pathway. This makes its mechanism additive to rather than redundant with insulin sensitizers, GLP-1 medications, and other metabolic interventions.
Can MOTS-c be combined with semaglutide or tirzepatide?
Yes -- the mechanisms are complementary. GLP-1 medications improve insulin secretion and reduce appetite. MOTS-c improves cellular insulin sensitivity and metabolic flexibility. Combining them targets metabolic dysfunction at multiple levels. Track fasting glucose carefully when combining to ensure glucose does not fall excessively.
Is MOTS-c the same as humanin?
Both MOTS-c and humanin are mitochondria-derived peptides but they are different compounds with different mechanisms. Humanin has primarily neuroprotective effects; MOTS-c has primarily metabolic effects.
How quickly should I expect lab improvements?
Most users running a full 8-week cycle see meaningful fasting glucose and HOMA-IR improvement at 4 weeks. Triglyceride and HbA1c changes are slower -- 8-12 weeks is a more realistic assessment window.
Is MOTS-c safe to run alongside testosterone optimization?
Yes -- no significant interactions are known. Both improve metabolic function through different pathways and are commonly used together in comprehensive longevity protocols.
The information in this article is for educational purposes only. It does not constitute medical advice. Always consult a licensed healthcare provider before starting any peptide protocol.
Written by Ryan -- Founder, MyProtocolStack. Last Updated: April 2026.
Enter your blood work in MyProtocolStack, run StackAI analysis, and get personalized insights based on your actual numbers -- not generic charts.
Start Free →